MDXG (MiMedx Group) Cyclically Adjusted Revenue per Share: $3.01 (As of Mar. 2026)


MDXG MiMedx Group Inc MDXG
53 GF Score
Price $4.11
GF Value $6.84
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Cyclically Adjusted Revenue per Share?

MiMedx Group MDXG -1.20% 53 Cyclically Adjusted Revenue per Share is $3.01 as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 53/100 and a GF Value™ of $6.84 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MiMedx Group's adjusted revenue per share for the three months ended in Mar. 2026 was $0.397. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.01 for the trailing ten years ended in Mar. 2026.

During the past 12 months, MiMedx Group's average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of MiMedx Group was 22.10% per year. The lowest was 6.70% per year. And the median was 15.80% per year.

As of today (2026-07-10), MiMedx Group's current stock price is $4.11. MiMedx Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $3.01. MiMedx Group's Cyclically Adjusted PS Ratio of today is 1.37.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MiMedx Group was 17.26. The lowest was 0.88. And the median was 2.97.


MiMedx Group  (NAS:MDXG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MiMedx Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.11/3.01
=1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MiMedx Group was 17.26. The lowest was 0.88. And the median was 2.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MiMedx Group Cyclically Adjusted Revenue per Share Related Terms


MiMedx Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MiMedx Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group Cyclically Adjusted Revenue per Share Chart

MiMedx Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.11 2.45 2.68 2.85 2.98

MiMedx Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.90 2.94 2.97 2.98 3.01

MDXG vs MNPR, FTH, BBOT: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, MiMedx Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Cyclically Adjusted PS Ratio falls into.


MDXG
53GF Score
MiMedx Group Inc MDXG
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiMedx Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MiMedx Group's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.397/330.2130*330.2130
=0.397

Current CPI (Mar. 2026) = 330.2130.

MiMedx Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.511 241.018 0.700
201609 0.573 241.428 0.784
201612 0.409 241.432 0.559
201703 0.638 243.801 0.864
201706 0.652 244.955 0.879
201709 0.720 246.819 0.963
201712 0.763 246.524 1.022
201803 0.740 249.554 0.979
201806 0.859 251.989 1.126
201809 0.821 252.439 1.074
201812 0.848 251.233 1.115
201903 0.625 254.202 0.812
201906 0.631 256.143 0.813
201909 0.811 256.759 1.043
201912 0.714 256.974 0.917
202003 0.574 258.115 0.734
202006 0.496 257.797 0.635
202009 0.593 260.280 0.752
202012 0.633 260.474 0.802
202103 0.548 264.877 0.683
202106 0.618 271.696 0.751
202109 0.570 274.310 0.686
202112 0.458 278.802 0.542
202203 0.528 287.504 0.606
202206 0.593 296.311 0.661
202209 0.597 296.808 0.664
202212 0.654 296.797 0.728
202303 0.627 301.836 0.686
202306 0.553 305.109 0.599
202309 0.546 307.789 0.586
202312 0.594 306.746 0.639
202403 0.565 312.332 0.597
202406 0.586 314.175 0.616
202409 0.567 315.301 0.594
202412 0.622 315.605 0.651
202503 0.589 319.799 0.608
202506 0.660 322.561 0.676
202509 0.760 324.800 0.773
202512 0.786 324.054 0.801
202603 0.397 330.213 0.397

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $3.01 mean?
MiMedx Group (MDXG) has a Cyclically Adjusted Revenue per Share of $3.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MiMedx Group and its competitors.
Is MiMedx Group's Cyclically Adjusted Revenue per Share too high?
MiMedx Group's current Cyclically Adjusted Revenue per Share is $3.01. Overall, MiMedx Group has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Cyclically Adjusted Revenue per Share compare to MNPR and FTH?
MiMedx Group's Cyclically Adjusted Revenue per Share of $3.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MiMedx Group and its competitors. MiMedx Group's current Cyclically Adjusted Revenue per Share is $3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.84, compared to a current price of $4.11 — trading 39.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $3.01. MiMedx Group's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Cyclically Adjusted Revenue per Share is $3.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $4.11 is trading 39.9% below its estimated GF Value™ of $6.84. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Cyclically Adjusted Revenue per Share: $3.01
  • GF Value™: $6.84 vs. price of $4.11 (39.9% below fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
53GF Score

Get the complete analysis for MDXG

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$6.84
GF Value